Impact of Histopathological Diagnosis with Ancillary Immunohistochemical Studies on Lung Cancer Subtypes Incidence and Survival: A Population-Based Study

Purpose. The aim of this study was to assess the impact of immunohistochemical- (IHC-) studies on incidence and survival of lung cancer histotypes.Patients and Methods. Lung cancers occurred in southern Switzerland between 1996 and 2010 were selected by the Ticino Cancer Registry and categorised into adenocarcinoma (AC), squamous-cell-carcinoma (SqCC), small-cell-carcinoma (SmCC), and large-cell carcinoma/non-small-cell lung cancer (LCC/NSCLC). Incidence rates, annual-percentage-change (APC), and two-year overall survival (OS) (follow-up: 31.12.2010) were performed.Results. 2467 cases were selected: 997 (40.4%) AC; 522 (21.2%) LCC/NSCLC, 378 (15.3%) SmCC, and 570 (23.1%) SqCC. Trend-analysis showed significant increase in AC (APC: 4.6; 95% CI: 3.1; 6.0) and decrease of LCC/NSCLC, with significant joinpoint in 2003 (APC: −14.7; 95% CI: −21.6; −7.1). Improved OS and decreased OS were detected in SqCC and LCC/NSCLC, respectively.Conclusions. This study highlights that diagnosis with ancillary immunohistochemical studies will change incidence and survival of precisely defined lung cancer subtypes. It calls attention to the need for cautious interpretation of studies and clinical trials, where the diagnosis was based on histology unaccompanied by IHC studies, and to the need of standardised diagnostic procedures.

Download Full-text

Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.

Journal of Clinical Oncology ◽

10.1200/jco.1985.3.11.1478 ◽

1985 ◽

Vol 3 (11) ◽

pp. 1478-1485 ◽

Cited By ~ 29

Author(s):

D Osoba ◽

J J Rusthoven ◽

K A Turnbull ◽

W K Evans ◽

F A Shepherd

Keyword(s):

Lung Cancer ◽

Cell Carcinoma ◽

Squamous Cell ◽

Cell Lung Cancer ◽

Performance Status ◽

Large Cell Carcinoma ◽

Large Cell ◽

Small Cell ◽

Entire Group ◽

Small Cell Lung

Fifty-three patients with recurrent and advanced stage (III and IV) non-small-cell lung cancer (NSCLC) were treated with a combination of bleomycin, etoposide (VP-16-213), and cis-diamminedichloroplatinum (BEP). Forty-eight patients were appraisable for response. The response rates were 44% for the entire group, 57% in 30 patients with combined squamous-cell and large-cell carcinoma, and 22% in 18 patients with adenocarcinoma (40%, 50%, and 19%, respectively, if patients not appraisable for response are included as nonresponders). The median survival time of patients with squamous-cell and large-cell carcinoma was slightly longer than that of patients with adenocarcinoma (23 weeks v 19 weeks). Patients with responsive disease survived significantly longer (median, 34 weeks) than did patients with unresponsive disease (median, 16 weeks) (P = .001). In the entire group, the median survival time of patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 was better (23 weeks) than of those with a status of 2 or 3 (15 weeks), but this difference was not seen in the subgroup with squamous-cell and large-cell carcinoma (24 weeks v 23 weeks, respectively). Thus, the performance status was not of prognostic value in the histologic subgroups experiencing the best response rate. There were two treatment-related deaths, but otherwise the toxicity of BEP was acceptable. Only four of the 119 treatment cycles were followed by fever even though there was significant neutropenia (0.5 X 10(9)/L) after 20 of 97 treatment cycles. The majority of patients receiving BEP experienced relief of cough, hemoptysis, pain, and fatigue associated with their disease. There was a good correlation between objective responses and palliation of symptoms. Thus, BEP offers good palliation, particularly for patients with squamous-cell and large-cell lung cancer.

Download Full-text

Lung Cancer - Part I

10.2310/im.1184 ◽

2019 ◽

Author(s):

Jeffrey Crawford ◽

John Strickler

Keyword(s):

Lung Cancer ◽

Squamous Cell Carcinoma ◽

Small Cell Lung Cancer ◽

Cell Carcinoma ◽

Squamous Cell ◽

Cell Lung Cancer ◽

Large Cell Carcinoma ◽

Large Cell ◽

Small Cell ◽

Small Cell Lung

In the United States, lung cancer is the second most common cancer, surpassed only by prostate cancer in men and breast cancer in women. But lung cancer is the leading cause of cancer deaths, accounting for 29% and 26% of all cancer-related deaths in men and women, respectively. The four major pathologic cell types of lung cancer are small cell carcinoma, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Because they have overlapping clinical behaviors and responses to treatment, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are generally grouped together in the category of non–small cell lung cancer (NSCLC). This review discusses both NSCLC and small cell lung cancer (SCLC), including lung cancer in those who have never smoked, prevention of lung cancer, with sections on diagnosis, biomarkers, treatment, and supportive care. This review contains 7 figures, 10 tables, and 74 references. Keywords: lung cancer, mediastinoscopy, chemoradiotherapy, TNM staging system, pulmonary parenchyma, segmentectomy

Download Full-text

Lung Cancer - Part I

10.2310/fm.1184 ◽

2019 ◽

Author(s):

Jeffrey Crawford ◽

John Strickler

Keyword(s):

Lung Cancer ◽

Squamous Cell Carcinoma ◽

Small Cell Lung Cancer ◽

Cell Carcinoma ◽

Squamous Cell ◽

Cell Lung Cancer ◽

Large Cell Carcinoma ◽

Large Cell ◽

Small Cell ◽

Small Cell Lung

Download Full-text

Lung Cancer Part II

10.2310/im.1672 ◽

2019 ◽

Author(s):

Jeffrey Crawford

Keyword(s):

Lung Cancer ◽

Squamous Cell Carcinoma ◽

Small Cell Lung Cancer ◽

Cell Carcinoma ◽

Squamous Cell ◽

Cell Lung Cancer ◽

Large Cell Carcinoma ◽

Large Cell ◽

Small Cell ◽

Small Cell Lung

In the United States, lung cancer is the second most common cancer, surpassed only by prostate cancer in men and breast cancer in women. But lung cancer is the leading cause of cancer deaths, accounting for 29% and 26% of all cancer-related deaths in men and women, respectively. The four major pathologic cell types of lung cancer are small cell carcinoma, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Because they have overlapping clinical behaviors and responses to treatment, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are generally grouped together in the category of non–small cell lung cancer (NSCLC). This review discusses treatment of both NSCLC and small cell lung cancer (SCLC). This review 2 figures, 19 tables, and 90 references. Keywords: lung cancer, mediastinoscopy, chemoradiotherapy, TNM staging system, pulmonary parenchyma, segmentectomy

Download Full-text

Lung cancer immunophenotypic profile: a tertiary health care institute’s experience with new WHO classification

International Journal of Scientific Reports ◽

10.18203/issn.2454-2156.intjscirep20211454 ◽

2021 ◽

Vol 7 (5) ◽

pp. 266

Author(s):

Jyoti Rajpoot ◽

Shweta Sushmita ◽

Charanjeet Ahluwalia ◽

Sufian Zaheer ◽

Rashmi Arora ◽

...

Keyword(s):

Lung Cancer ◽

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Who Classification ◽

Squamous Carcinoma ◽

Large Cell Carcinoma ◽

Large Cell ◽

Small Cell ◽

Immunohistochemical Examination ◽

Invaluable Tool

Background: Lung cancer is one of the most common cancers accounting for 13% of all new cancer cases and 19% of cancer related deaths all over world. In India it constitutes 6.9% of all new cancer cases and 9.3% of all cancer related deaths in both sexes. The new 2015 WHO Classification recommends to apply immunohistochemistry, when possible, for small biopsies/cytology, and also for resected specimens.Methods: An observational study with 113 cases between January 2017 to January 2019 received in the department of pathology. Morphological and immunohistochemical examination was done in each case.Results: Based on morphology and immunohistochemistry cases were classified as adenocarcinoma, squamous cell carcinoma, adeno-squamous carcinoma, small cell carcinoma, and large cell carcinoma in accordance with 2015 WHO classification.Conclusions: Classification and staging of lung cancer at the time of diagnosis is the most important predictor of survival in the era of specific targeted therapy. Immunohistochemistry is proved to be an invaluable tool for definite categorization of lung cancer cases.

Download Full-text

Lung Cancer Part II

10.2310/fm.1672 ◽

2019 ◽

Author(s):

Jeffrey Crawford

Keyword(s):

Lung Cancer ◽

Squamous Cell Carcinoma ◽

Small Cell Lung Cancer ◽

Cell Carcinoma ◽

Squamous Cell ◽

Cell Lung Cancer ◽

Large Cell Carcinoma ◽

Large Cell ◽

Small Cell ◽

Small Cell Lung

In the United States, lung cancer is the second most common cancer, surpassed only by prostate cancer in men and breast cancer in women. But lung cancer is the leading cause of cancer deaths, accounting for 29% and 26% of all cancer-related deaths in men and women, respectively. The four major pathologic cell types of lung cancer are small cell carcinoma, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Because they have overlapping clinical behaviors and responses to treatment, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are generally grouped together in the category of non–small cell lung cancer (NSCLC). This review discusses treatment of both NSCLC and small cell lung cancer (SCLC). This review 2 figures, 19 tables, and 90 references. Keywords: lung cancer, mediastinoscopy, chemoradiotherapy, TNM staging system, pulmonary parenchyma, segmentectomy

Download Full-text

A case of small cell carcinoma of the lung differentiated toward large cell carcinoma and adenocarcinoma during treatment.

The Journal of the Japanese Society of Clinical Cytology ◽

10.5795/jjscc.30.507 ◽

1991 ◽

Vol 30 (3) ◽

pp. 507-511

Author(s):

Hitoshi HIRATA ◽

Yutaka MIZUSHIMA ◽

Saburo YANO ◽

Mikio KITASAWA ◽

Ken FUKUMURA ◽

...

Keyword(s):

Cell Carcinoma ◽

Small Cell Carcinoma ◽

Large Cell Carcinoma ◽

Large Cell ◽

Small Cell

Download Full-text

The Descriptive Epidemiology of Primary Lung Cancer in an Alberta Cohort with a Mutivariate Analysis of Survival to Two Years

Canadian Respiratory Journal ◽

10.1155/2003/729635 ◽

2003 ◽

Vol 10 (8) ◽

pp. 435-441 ◽

Cited By ~ 3

Author(s):

Sandor J Demeter ◽

Chester Chmielowiec ◽

Wayne Logus ◽

Pauline Benkovska-Angelova ◽

Philip Jacobs ◽

...

Keyword(s):

Lung Cancer ◽

Squamous Cell Carcinoma ◽

American Literature ◽

Cell Carcinoma ◽

Squamous Cell ◽

Primary Lung Cancer ◽

Case Fatality ◽

Nonsmall Cell Lung Cancer ◽

Small Cell ◽

The Impact

BACKGROUND: Lung cancer contributes significantly to cancer morbidity and mortality. Although case fatality rates have not changed significantly over the past few decades, there have been advances in the diagnosis, staging and management of lung cancer.OBJECTIVE: To describe the epidemiology of primary lung cancer in an Alberta cohort with an analysis of factors contributing to survival to two years.PATIENTS AND METHODS: Six hundred eleven Albertans diagnosed with primary lung cancer in 1998 were identified through the Alberta Cancer Registry. Through a chart review, demographic and clinical data were collected for a period of up to two years from the date of diagnosis.RESULTS: The mean age at diagnosis was 66.5 years. The majority of cases (92%) were smokers. Adenocarcinoma, followed by squamous cell carcinoma, were the most frequent nonsmall cell lung cancer histologies. Adenocarcinoma was more frequent in women, and squamous cell carcinoma was more frequent in men. The overall two- year survival rates for nonsmall cell, small cell and other lung cancers were 24%, 10% and 13%, respectively. In multivariate analysis, stage, thoracic surgery and chemotherapy were significantly associated with survival to two years in nonsmall cell carcinoma; only stage and chemotherapy were significant in small cell carcinoma.CONCLUSIONS: This study provides a Canadian epidemiological perspective, which generally concurs with the North American literature. Continued monitoring of the epidemiology of lung cancer is essential to evaluate the impact of advances in the diagnosis, staging and management of lung cancer. Further clinical and economic analysis, based on data collected on this cohort, is planned.

Download Full-text

Rare Occurrence of a Poorly Differentiated Neuroendocrine Tumor of the Bladder

Case Reports in Medicine ◽

10.1155/2017/4812453 ◽

2017 ◽

Vol 2017 ◽

pp. 1-4 ◽

Cited By ~ 2

Author(s):

Katherine Dowd ◽

Charles Rotenberry ◽

Douglas Russell ◽

Mitchell Wachtel ◽

Werner de Riese

Keyword(s):

Cell Carcinoma ◽

Neuroendocrine Tumor ◽

Survival Data ◽

Large Cell Carcinoma ◽

Large Cell ◽

Disease Recurrence ◽

Small Cell ◽

Treatment Regimens ◽

Poorly Differentiated ◽

Carcinoma Of The Bladder

Neuroendocrine tumors rarely occur in the urinary bladder. They can be carcinomatous, subdivided into small cell and large cell pathology. Small cell carcinoma of the bladder is a rarity that may present at an advanced pathologic stage. No treatment regimens have been standardized for local or metastatic disease. Review of the recent literature shows equivalent survival data for localized disease treated with chemoradiotherapy combined with either bladder sparing surgery or radical cystectomy. Patients with significant comorbidities are an additional challenge. We report a case of poorly differentiated neuroendocrine tumor of the bladder, which could not be classified as small or large cell carcinoma, complicated by significant comorbidities. After management with transurethral resection of the tumor, adjuvant chemotherapy, and radiation, the patient is alive and asymptomatic nearly 1 year after initial TURBT with no evidence of disease recurrence.

Download Full-text